Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Ph 1/2a CARMA study of ELC-301 continues as planned following the safety committee’s assessment of cohort 1

April 22, 2025

Clinical development of nemvaleukin to discontinue following review of data from Ph 2 ARTISTRY-6 and Ph 3 ARTISTRY-7 trials

April 22, 2025

First Patient Treated in Ph 1 Trial of PHST001 for Patients with Advanced Solid Tumors

April 22, 2025

Enrollment completed in Ph 2 CRDF-004 Trial of Onvansertib in 1L RAS-mutated Metastatic CRC

April 22, 2025

First Patient enrolled in Ph 2 Trial of Ethanol-Free Carmustine in High-Dose Chemotherapy Prior to Transplant in Patients with HL or NHL

April 22, 2025

First Patient Dosed in Ph 2 Trial of HLX22 + T-Dxd in HER2-low, HR-positive Breast cancer patients

April 22, 2025

First Patient Dosed in Ph 1/2 Study for KSQ-004EX in advanced solid tumors

April 16, 2025

Ph 3 AdvanTIG-302 trial unlikely to meet primary endpoint; Ociperlimab (BGB-A1217) Program to be discontinued

April 16, 2025

New clinical trial of GPC-100 (burixafor) planned in AML

April 15, 2025

First Patient Enrolled in Ph 1b FORTRESS Trial of NG-350A in Locally Advanced Rectal Cancer Patients

April 15, 2025

First Patient Dosed in Ph 1 trial of REC-3565 for R/R B-cell Lymphomas

April 15, 2025

Near Completion of Ph 1 Enrollment for NEO212 Brain Cancer Therapy Announced

April 15, 2025

Initial Clinical Trial Site for Ph 1 Trial of CER-1236 in AML Announced

April 15, 2025

First Subject Dosed for Ph 1b/2 Trial of HLX43 + Serplulimab

April 15, 2025

First Patient Dosed in Ph 3 MIRACLE Trial of Annamycin and Ara-C in R/R AML patients

April 8, 2025

Patient with HPV+ HNSCC dosed in Ph 1 ACESOT-1051 Trial

April 8, 2025

First Patient Dosed in ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma

April 8, 2025

First Patient Dosed in Ph 1 Study of VVD-159642 for Treatment of Advanced Solid Tumors

April 8, 2025

First Patient Dosed in the Ph 3 Registrational Trial of ICP-248 + Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

April 2, 2025

Development of EO-3021 to be Discontinued

March 26, 2025

Vobramitamab duocarmazine (vobra duo) program to be discontinued

March 26, 2025

First Participant Dosed in Ph 3 Study of IBI354 for Platinum-resistant Ovarian Cancer

March 26, 2025

Ph 2 FIRCE-1 study of firicabtagene autoleucel (firi-cel) to be discontinued

March 26, 2025

Dosing Completed in the First Cohort of Ph 1 Study of NKT3964

March 18, 2025

Multikine Confirmatory Ph 3 Trial  in newly diagnosed locally advanced head and neck cancer patients to be Initiated

March 18, 2025
Page1 Page2 Page3 Page4 … Page23

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.